Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fampridine immediate-release

Drug Profile

Fampridine immediate-release

Alternative Names: 4-Aminopyridine immediate release; 4-AP - Neurorecovery; 4-AP IR; Ampydin IR; Fampridine IR

Latest Information Update: 12 Feb 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurorecovery
  • Class Aminopyridines; Neuroprotectants; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Guillain-Barre syndrome

Highest Development Phases

  • Suspended Guillain-Barre syndrome

Most Recent Events

  • 22 Sep 2014 Biomarkers information updated
  • 12 Feb 2008 Suspended - Phase-II for Guillain-Barre syndrome in USA (PO)
  • 05 Feb 2008 Acorda Therapeutics acquires ownership of Neurorecovery's fampridine immediate-release product
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top